Vevo
Diego Borges-Rivera is a skilled computational biologist with extensive experience in the field, currently working at Vevo Therapeutics since September 2022 and concurrently at Dogodan Therapeutics, Inc. since August 2022. Prior roles include positions at Enko, Goldfinch Bio, and DeepBiome Therapeutics, where expertise in scRNA-seq data analysis and computational infrastructure was developed. Diego's academic background includes a PhD from the Massachusetts Institute of Technology, focusing on cis-regulatory elements and genome analysis, as well as a B.S. from Carnegie Mellon University in computational biology. Experience also includes positions at the Broad Institute and Carnegie Mellon University, enhancing a robust foundation in computational biology and data science.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.